Bladder Cancer

Latest News

First commercial doses of N-803 for NMIBC administered across US
First commercial doses of N-803 for NMIBC administered across US

June 20th 2024

N-803 was approved by the FDA in April 2024 for the treatment of patients with BCG-unresponsive NMIBC carcinoma in situ with or without papillary tumors.

Cretostimogene grenadenorepvec made available through expanded access program
Cretostimogene grenadenorepvec made available through expanded access program

June 18th 2024

UGN-102 demonstrates long-term durability in NMIBC
UGN-102 demonstrates long-term durability in NMIBC

June 13th 2024

Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC
Cretostimogene Grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC

June 5th 2024

Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma
Sacituzumab govitecan falls short in phase 3 trial for metastatic urothelial carcinoma

May 31st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.